

CITATION REPORT

List of articles citing

Pharmaceutical Pricing and Reimbursement in Japan: For Faster, More Complete Access to New Drugs

DOI: 10.1177/2168479015619202

Therapeutic Innovation and Regulatory Science, 2016,
50, 361-367.

Source: <https://exaly.com/paper-pdf/65330426/citation-report.pdf>

Version: 2024-04-05

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
16	Evaluating the Effectiveness of Repricing for Market Expansion in the Japanese Drug Pricing System. <i>Therapeutic Innovation and Regulatory Science</i> , 2016 , 50, 751-758	1.2	10
15	Pricing of innovative drugs: correlation between incremental cost and survival gain in four countries. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 309-11	5.4	2
14	Drugs Targeted for Price Cutting in Japan: The Case of Price Revisions Based on the Divergence of Official Versus Delivery Prices. <i>Therapeutic Innovation and Regulatory Science</i> , 2017 , 51, 597-603	1.2	5
13	Quantitative Assessment of Premium Rates for Clinical Usefulness in New Drug Price Calculation in Japan. <i>Therapeutic Innovation and Regulatory Science</i> , 2017 , 51, 582-588	1.2	2
12	Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan. <i>Clinical Therapeutics</i> , 2018 , 40, 284-295	3.5	2
11	The pharmaceutical market and drug development prognosis in Japan: Current and future perspectives according to pharmacological classes. <i>Journal of Generic Medicines</i> , 2018 , 14, 70-80	0.2	4
10	Japan oncology market overview: Current and future perspectives. <i>Journal of Generic Medicines</i> , 2019 , 15, 104-114	0.2	1
9	Willingness to pay for QALY: perspectives and contexts in Japan. <i>Journal of Medical Economics</i> , 2019 , 22, 1041-1046	2.4	6
8	Global guidelines trends and controversies in lower limb venous and lymphatic disease: Narrative literature revision and experts' opinions following the vWINTER international meeting in Phlebology, Lymphology & Aesthetics, 23-25 January 2019. <i>Phlebology</i> , 2019 , 34, 4-66	2	29
7	Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy. <i>Diabetes Therapy</i> , 2019 , 10, 1347-1356	3.6	3
6	Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview. <i>Journal of Market Access & Health Policy</i> , 2019 , 7, 1601060	3.7	17
5	Current status on securing pharmaceutical drug price information in Japan. <i>International Journal of Healthcare Management</i> , 2019 , 1-6	1.4	
4	Analyzing Upward Deviation of Actual vs Predicted Drug Sales in Japan for a Reasonable Drug-Pricing Policy. <i>Therapeutic Innovation and Regulatory Science</i> , 2019 , 2168479019860123	1.2	
3	Reimbursement Lag of New Drugs Under Taiwan's National Health Insurance System Compared With United Kingdom, Canada, Australia, Japan, and South Korea. <i>Clinical and Translational Science</i> , 2020 , 13, 916-922	4.9	2
2	Impact of Depression Onset and Treatment on the Trend of Annual Medical Costs in Japan: An Exploratory, Descriptive Analysis of Employer-Based Health Insurance Claims Data. <i>Advances in Therapy</i> , 2021 , 1	4.1	0
1	Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in Japan.. <i>BMC Health Services Research</i> , 2021 , 21, 1329	2.9	1